Human, financial, and other resources have been and continue to be reallocated from TB treatment and prevention to the COVID-19 response.
In September of 2019, the World Health Organization (WHO) and Global Preparedness Monitoring Board (GPMB) published a report with a warning—our risk of a global pandemic was on the rise, and the world was not prepared. Three months later, in December 2019, the first COVID-19 cases were reported to the World Health Organization.
As infectious diseases evolve, the medical community has been working to meet the challenge by updating and improving the tools we use to combat infections. Right now, biopharmaceutical research companies have 421 medicines and vaccines in development to treat or prevent fungal, bacterial, and viral infections.
Three well-established infectious diseases—Tuberculosis, malaria, and HIV—are poised to kill millions worldwide, with decades of healthcare progress that could be lost due to disruptions caused by COVID-19. Even under normal circumstances, the toll these three diseases exact worldwide is staggering.